US FDA declines to approve Aquestive's oral drug for allergic reactions
02/02/2026 12:05
Feb 2 (Reuters) - The U.S. Food and Drug administration has declined to approve Aquestive Therapeutics' AQST.O oral drug for severe allergic reactions, the company said on Monday. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Aquestive rises on US licensing deal for seizure drug with Eton Pharma